400 Section - Effect of Tirzepatide on knee pain and quality of life in obese knee osteoarthritis patients

: Assess the effect of Tirzepatide on knee pain and quality of life in obese knee osteoarthritis patients

Design:

 a prospective double-blind study

Informed consent was signed by all participants 

Obese  knee osteoarthritis patients were included and randomized into two groups; group I ; 92 patients and group II control;35 patients.

All  patients had the following initially: Body mass index (BMI), Visual Analogue Scale for pain (VAS), Lequesene Index, detailed musculoskeletal exam, Glycosylated Hemoglobin (HgA1c).

all patients were instructed for reduced -calorie diet , increase physical activity and given the same type of non-steroidal anti-inflammatory drugs and or acetaminophen as needed for pain for 8 weeks. Group I received Tirzepatide 2.5mg/0.5ml subcutaneously weekly for 4 weeks then 5mg /week for another 4 weeks

After 8 weeks repeat measurement of BMI, HgA1c, VAS, Lequesene index for all patients

 

Results:

Group I;72 females, 20males,  group II: 30 female ,5 males. Mean age Group I 50.17±12.03, group II 50.9±12.3. No significant difference regarding age and sex. Mean BMI initially  Group I 38.1±6.22 , Group II 38.9±4.1 After 8 weeks ,BMI Group I significantly drop  34.96±6.55, Group II BMI 38.1±3.6, with significant difference  (p=0.005)

Mean HgA1c initially; Group I 5.57±0.61, Group II 5.7±0.3, without significant difference. After 8 weeks Group I significantly decreased HgA1c 5.41 ± 0.42, Group II ;5.7±0.3,  significant difference between groups.

Initial VAS of Group I 8.71±1.05, Group II VAS 7.9±1.2, without significant difference in between, finally Group I VAS significantly drop 6.45±1.44  , Group II VAS significantly drop 7.3±1.1  with significant higher drop-in Group I (p=0.001).

Mean Lequesene Index Group I 12.05±2.06 ,at the end ; 9.82±2.39 (p=0.001). Group II was 13.9±3.7decreased significantly 13.5±4. With significant higher drop-in Group I

 

Conclusion: Tirzepatide significantly reduced body weight with significant positive influence on knee pain and quality of life in obese knee osteoarthritis patients